News
February 10, 2009
I-vitro antiretroviral activities indicated that compound 7-(4-((6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2-oxo-2H-benzo[d] [1,3]oxazin-1 (4H)-yl)methyl)-3-methylpiperazin-l -yl)-1-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid (4i) was equipotent to efavirenz with EC(50) of 2.4 nM. Compound 4i also inhibited M. tuberculosis with minimum inhibitory concentration of 0.2 microg/mL.
February 10, 2009
A series of hydrazone and 3-nitrovinyl analogs of indole-3-carboxaldehydes and related compounds were synthesized and screened for antitubercular activity against Mycobacterium tuberculosis H37R(V). Several showed inhibitory activity against Mtb.
January 26, 2009
Described in this article are the early efforts in the development of novel signal transduction inhibitory anti-mycobacterial drugs using a multiple target approach via virtual screening, with special emphasis on the kinase inhibitory field.
January 26, 2009
Lipiarmycin showed excellent bactericidal activity against MTB and lacks cross-resistance to standard anti-TB drugs.
January 26, 2009
Investigation of the roots of Beilschmiedia erythrophloia has led to the isolation of seven new endiandric acid analogues. Two constituents, erythrophloin C (3) and suberosol B (8), exhibited antitubercular activity against Mtb H37Rv, showing MIC values of 50 and 28.9 μg/mL, respectively.
January 26, 2009
New hydrazide derivatives of imidazo[1,2-a]pyridine were synthesized and evaluated for antituberculosis activity. Results show significant inhibition of Mtb H37Rv.
January 26, 2009
Four new partially acylated tetrasaccharides of 11-hydroxyhexadecanoic acid (1−4) were isolated from a methanolic extract of Ipomoea tyrianthina and revealed antimycobacterial activity.
January 26, 2009
5′-O-[N-(salicyl)sulfamoyl]adenosine (Sal-AMS) is a prototype for a new class of antitubercular agents that inhibit the aryl acid adenylating enzyme (AAAE) known as MbtA involved in biosynthesis of the mycobactins. The most potent Mbta inhibitors displayed in vitro antitubercular activity superior to most current first line TB drugs.
January 26, 2009
HIV-positive infants are over 20 times more likely to develop tuberculosis than their HIV-negative counterparts, researchers from South Africa report in the current issue of Clinical Infectious Diseases.
January 20, 2009
Peg Willingham, Senior Director of the Aeras Global TB Vaccine Foundation, talks about the status of the fight against TB in the wake of the 2008 U.S. elections and in 2009.
January 20, 2009
A pivotal Phase III trial of a shorter, four-month course for TB treatment including the oral fluoroquinolone antibiotic gatifloxacin has taken a significant step forward after the enrolment quota of 1836 volunteer patients was reached in African study sites in October. These patients will complete treatment in the second quarter of 2009.
January 20, 2009
To address patient non-compliance in TB control programmes, the Council for Scientific and Industrial Research in South Africa is seeking to reformulate first-line TB drugs into nanoparticulate oral dosage form for controlled release over an extended period in order to reduce total doses and treatment period and improve patient compliance.
January 20, 2009
Masses of immune cells that form as a hallmark of tuberculosis (TB) have long been thought to be the body's way of trying to protect itself by literally walling off the bacteria.
But a new study in the January 9th issue of the journal Cell, a Cell Press publication, offers evidence that the TB bacteria actually sends signals that encourage the growth of those organized granuloma structures, and for good reason: each granuloma serves as a kind of hub for the infectious bugs in the early stages of infection, allowing them to expand further and spread throughout the body.
January 20, 2009
Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational.
December 31, 2008
Two persons have been named winners of $20,000 each in the InnoCentive Challenge by the online research collaboration company InnoCentive, Inc., and the Global Alliance for TB Drug Development. The challenge, which is also supported by the Rockefeller Foundation, seeks solutions for the most efficient and least expensive method of producing the new TB drug candidate PA-824.
December 31, 2008
Multi-drug resistant tuberculosis is nearly twice as common in China as in the rest of the world.
December 31, 2008
The Ugandan government and Foundation for Innovative New Diagnostics recently opened a laboratory in Wandegeya, Uganda, that can diagnose multi-drug resistant tuberculosis and extensively drug-resistant TB within one day.
December 4, 2008
September 2008 marked the beginning of a new federal program intended to promote the development of pharmaceutical products for so-called neglected diseases — infectious diseases that disproportionately affect poor populations in developing countries.
December 4, 2008
Although more than 90 of tuberculosis patients in Nepal complete treatment successfully, inadequate DOTS performance could be contributing to an increase in multi-drug resistant TB in the country. According to Dirgh Bam, MDR-TB accounts for up to 1.8% of new TB infections in Nepal.
November 21, 2008
Scientists at Rutgers University describe a group of antibiotic compounds first isolated decades ago from naturally occurring antibacterial substances in soil. A compound called myxopyronin is among these antibiotic compounds, and it shows great potential.
Displaying 101 through 120 of 836 items.
